Holen Sie sich die Stockscreener-App
1.32
2.33%
0.03
Handel nachbörslich:
1.28
-0.04
-3.03%
Schlusskurs vom Vortag:
$1.29
Offen:
$1.26
24-Stunden-Volumen:
114.96K
Relative Volume:
0.05
Marktkapitalisierung:
$5.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.56M
KGV:
-0.2503
EPS:
-5.274
Netto-Cashflow:
$-7.76M
1W Leistung:
+15.79%
1M Leistung:
+5.60%
6M Leistung:
-75.46%
1J Leistung:
-86.25%
1-Tages-Spanne:
$1.26
$1.37
1-Wochen-Bereich:
$1.13
$1.37
52-Wochen-Spanne:
$1.10
$9.899
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Firmenname
Dermata Therapeutics Inc
Sektor
Branche
Telefon
(858)-223-0882
Adresse
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.32 | 5.19M | 0 | -7.56M | -7.76M | -5.274 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Dermata Therapeutics Inc Aktie (DRMA) Neueste Nachrichten
Take Profit: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsQuarterly Risk Review & Reliable Intraday Trade Plans - baoquankhu1.vn
DRMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Plus Therapeutics Inc (XMP0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Dermata shares rise after USPTO issues patent notice of allowance - MSN
Dermata receives Australian patent acceptance for topical filler - Investing.com Australia
Dermata Therapeutics Receives Australian Patent Acceptance for Bioneedle Dermal Filler Delivery System - geneonline.com
Dermata receives Australian patent acceptance for topical filler By Investing.com - Investing.com Canada
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System - The Batesville Daily Guard
Dermata clears Australian patent hurdle for topical dermal fillers - Stock Titan
Maxim Group Maintains Dermata Therapeutics(DRMA.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Guidance Update: Will Dermata Therapeutics Inc Equity Warrant benefit from AI trendsMarket Sentiment Report & Verified Short-Term Plans - baoquankhu1.vn
Tangible book value per share of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Total debt per share of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Aug Levels: Will Dermata Therapeutics Inc benefit from seasonality2026 Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Quarterly Trades: Is Dermata Therapeutics Inc stock forming a cup and handleQuarterly Portfolio Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Dermata Therapeutics Reports Increased Losses in FY Earnings - Intellectia AI
Dermata Therapeutics 2025 Financial Update - AlphaStreet
Dermata Therapeutics Inc stock rises amid market gains - Intellectia AI
Southland Holdings, Inc. (SLND) Reports Wider Q4 Loss Than Expected - news.alphastreet.com
Dermata Therapeutics Announces Strategic Pivot to DTC Skincare with Tome Brand and Plans 2026 Product Launch - Minichart
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 - Bitget
Dermata Therapeutics 10-K: $7.56M net loss, operating expenses $7.77M - TradingView
Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Dermata Therapeutics (NASDAQ: DRMA) pivots from Rx acne to Tome OTC skincare - Stock Titan
Dermata (NASDAQ: DRMA) shifts to DTC skincare as 2025 loss shrinks - Stock Titan
Analyst Downgrade: Will Dermata Therapeutics Inc benefit from AI trendsLong Setup & Precise Swing Trade Alerts - baoquankhu1.vn
Dermata Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Risk Recap: Is Dermata Therapeutics Inc Equity Warrant a strong candidate for buy and hold2026 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Fennec Pharmaceuticals Inc. (FENC) Misses Q4 EPS Estimates - news.alphastreet.com
If You Invested $1,000 in Protagenic Therapeutics Inc (PTIX) - Stock Titan
If You Invested $1,000 in THERIVA BIOLOGICS INC (TOVX) - Stock Titan
Valuation Update: Is Dermata Therapeutics Inc. Equity Warrant stock risky to hold now2026 Summary & Safe Entry Point Identification - baoquankhu1.vn
Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch - timothysykes.com
Dermata Therapeutics Strategically Pivots with New Skincare Launch - StocksToTrade
Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment - timothysykes.com
Why Planet Labs Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Sahm
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Dermata Therapeutics Ramps Up Skincare Division with New VP Appointment - StocksToTrade
Dermata’s Strategic Pivot: New Skincare Line on the Horizon - timothysykes.com
Stay updated with the stocks that are on the move in today's pre-market session. - ChartMill
Dermata Gears Up For First Once-Weekly Acne Kit Launch, Eyeing A Slice Of $3.8B Market - RTTNews
12 Health Care Stocks Moving In Friday's Pre-Market SessionAzitra (AMEX:AZTR), Bullfrog AI Hldgs (NASDAQ:BFRG) - benzinga.com
Get insights into the top gainers and losers of Thursday's after-hours session. - ChartMill
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Published on: 2026-03-20 05:04:24 - baoquankhu1.vn
Trevi Therapeutics (TRVI) Q4 Loss Narrows to $0.06/Share vs $0.10 Estimate, 37% Better Than Expected - AlphaStreet
Dermata Therapeutics (DRMAW) Expected to Announce Earnings on Wednesday - Defense World
Dermata Therapeutics (DRMA) SVP adds 1,000 shares in insider buy - stocktitan.net
CEO Change: Whats the outlook for Dermata Therapeutics Incs sectorQuarterly Profit Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Finanzdaten der Dermata Therapeutics Inc-Aktie (DRMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):